blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3331884

EP3331884 - UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.04.2021
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  15.05.2020
FormerGrant of patent is intended
Status updated on  13.02.2020
FormerRequest for examination was made
Status updated on  07.01.2020
FormerGrant of patent is intended
Status updated on  29.09.2019
FormerRequest for examination was made
Status updated on  11.05.2018
FormerThe international publication has been made
Status updated on  02.12.2016
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024 [2024/42]
Applicant(s)For all designated states
Kyorin Pharmaceutical Co., Ltd.
6, Kanda Surugadai 4-chome
Chiyoda-ku
Tokyo 101-8311 / JP
[2018/24]
Inventor(s)01 / FUJII, Kiyoshi
c/o WATARASE Research Center
KYORIN PHARMACEUTICAL CO. LTD.
1848
Nogi, Nogi-machi
Shimotsuga-gun Tochigi 329-0114 / JP
02 / UMEI, Kentaro
c/o KYORIN HOLDINGS INC. 6
Kanda Surugadai 4-chome
Chiyoda-ku
Tokyo 101-8311 / JP
03 / TAKAHASHI, Hiroyasu
138-5, Daigahara, Terukoshi, Tsukidate-aza
Kurihara-shi Miyagi 9872233 / JP
04 / SHIBASAKI, Mitsuhito
c/o WATARASE Research Center
KYORIN PHARMACEUTICAL CO. LTD.
1848
Nogi, Nogi-machi
Shimotsuga-gun Tochigi 329-0114 / JP
05 / OHATA, Kohei
c/o WATARASE Research Center
KYORIN PHARMACEUTICAL CO. LTD.
1848
Nogi, Nogi-machi
Shimotsuga-gun Tochigi 329-0114 / JP
 [2018/24]
Representative(s)Dehns
St. Bride's House
10 Salisbury Square
London EC4Y 8JD / GB
[2020/25]
Former [2018/24]Dehns
St. Brides House
10 Salisbury Square
London EC4Y 8JD / GB
Application number, filing date16729077.426.05.2016
[2018/24]
WO2016JP02557
Priority number, dateJP2015010722727.05.2015         Original published format: JP 2015107227
[2018/24]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016189876
Date:01.12.2016
Language:EN
[2016/48]
Type: A1 Application with search report 
No.:EP3331884
Date:13.06.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 01.12.2016 takes the place of the publication of the European patent application.
[2018/24]
Type: B1 Patent specification 
No.:EP3331884
Date:17.06.2020
Language:EN
[2020/25]
Search report(s)International search report - published on:EP01.12.2016
ClassificationIPC:C07D487/04, C07D263/26, C07D207/273, C07D498/04, C07D211/76, C07D307/22, A61K31/4985, A61P35/00, A61P37/00, A61P11/00, A61P25/28
[2018/24]
CPC:
A61K31/4985 (EP,US); C07D307/22 (EP,KR,US); C07D211/76 (EP,CN,KR,US);
A61K31/17 (KR); A61K31/34 (KR); A61K31/343 (EP,US);
A61K31/381 (EP,US); A61P11/00 (EP,CN); A61P25/00 (EP,CN);
A61P25/04 (EP); A61P25/28 (EP); A61P29/00 (EP,CN,KR);
A61P31/04 (CN); A61P31/10 (EP); A61P31/12 (CN);
A61P31/18 (EP,CN); A61P35/00 (EP,CN); A61P37/00 (EP);
A61P37/02 (EP); A61P37/06 (CN); A61P37/08 (EP,CN);
A61P43/00 (EP); A61P9/00 (EP); C07D207/273 (EP,KR,US);
C07D263/26 (EP,US); C07D487/04 (EP,CN,KR,US); C07D498/04 (EP,CN,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/24]
Extension statesBA28.03.2018
ME28.03.2018
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:HARNSTOFFDERIVAT ODER PHARMAZEUTISCH AKZEPTABLES SALZ DAVON[2018/24]
English:UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF[2018/24]
French:DÉRIVÉ DE L'URÉE OU SEL PHARMACOLOGIQUEMENT ACCEPTABLE DE CE DERNIER[2018/24]
Entry into regional phase28.03.2018National basic fee paid 
28.03.2018Designation fee(s) paid 
28.03.2018Examination fee paid 
Examination proceduredeletedDeletion: Application deemed to be withdrawn, date of legal effect  [2018/24]
02.02.2018Despatch of communication that the application is deemed to be withdrawn, reason: filing fee / search fee not paid in time  [2018/24]
28.03.2018Examination requested  [2018/24]
28.03.2018Date on which the examining division has become responsible
19.10.2018Amendment by applicant (claims and/or description)
30.09.2019Communication of intention to grant the patent
19.12.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
14.02.2020Communication of intention to grant the patent
10.05.2020Fee for grant paid
10.05.2020Fee for publishing/printing paid
10.05.2020Receipt of the translation of the claim(s)
Opposition(s)18.03.2021No opposition filed within time limit [2021/21]
Request for further processing for:28.03.2018Request for further processing filed
28.03.2018Full payment received (date of receipt of payment)
Request granted
02.05.2018Decision despatched
The application is deemed to be withdrawn due to non-payment of the filing fee
28.03.2018Request for further processing filed
28.03.2018Full payment received (date of receipt of payment)
Request granted
02.05.2018Decision despatched
The application is deemed to be withdrawn due to non-payment of the examination fee
28.03.2018Request for further processing filed
28.03.2018Full payment received (date of receipt of payment)
Request granted
02.05.2018Decision despatched
28.03.2018Request for further processing filed
28.03.2018Full payment received (date of receipt of payment)
Request granted
02.05.2018Decision despatched
The application is deemed to be withdrawn due to non-payment of designation fees
TR, SM, SK, SI, SE, RS, RO, PT, PL, NO, NL, MT, MK, MC, LV, LU, LT, IT, IS, IE, HU, HR, GR, GB, FR, FI, ES, EE, DK, DE, CZ, CY, CH, BG, BE, AT, AL
28.03.2018Request for further processing filed
28.03.2018Full payment received (date of receipt of payment)
Request granted
02.05.2018Decision despatched
Fees paidRenewal fee
11.05.2018Renewal fee patent year 03
15.05.2019Renewal fee patent year 04
31.03.2020Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU26.05.2016
AL17.06.2020
AT17.06.2020
CY17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
MC17.06.2020
MK17.06.2020
MT17.06.2020
NL17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
[2024/42]
Former [2024/22]HU26.05.2016
AL17.06.2020
AT17.06.2020
CY17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
MC17.06.2020
MK17.06.2020
NL17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
Former [2023/33]HU26.05.2016
AL17.06.2020
AT17.06.2020
CY17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
MC17.06.2020
NL17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
Former [2023/30]AL17.06.2020
AT17.06.2020
CY17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
MC17.06.2020
NL17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
Former [2022/07]AL17.06.2020
AT17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
MC17.06.2020
NL17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
Former [2021/24]AL17.06.2020
AT17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
NL17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
Former [2021/21]AL17.06.2020
AT17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
NL17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
Former [2021/10]AL17.06.2020
AT17.06.2020
CZ17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
NL17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
Former [2021/09]AL17.06.2020
AT17.06.2020
CZ17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
NL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
PT19.10.2020
Former [2021/04]AL17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
NL17.06.2020
RS17.06.2020
SE17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
Former [2021/01]FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
RS17.06.2020
SE17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
Former [2020/51]FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
RS17.06.2020
SE17.06.2020
NO17.09.2020
GR18.09.2020
Former [2020/50]FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
SE17.06.2020
NO17.09.2020
GR18.09.2020
Former [2020/48]FI17.06.2020
LT17.06.2020
SE17.06.2020
NO17.09.2020
Former [2020/47]LT17.06.2020
NO17.09.2020
Cited inInternational search[X]WO2013063214  (MERCK SHARP & DOHME [US], et al) [X] 1,3,5,6,10-14 * claims 1,21 ** page 281; compound 580 *;
 [A]WO2013071203  (ALLERGAN INC [US], et al) [A] 1-14 * claim 1 * * pages 37-39 *;
 [A]WO2013070600  (ALLERGAN INC [US], et al) [A] 1-14 * claim 1 * * pages 22-24 *;
 [IP]WO2015079692  (KYORIN SEIYAKU KK [JP]) [IP] 1 * claim 1 *;
 [E]WO2016095089  (MERCK SHARP & DOHME [US], et al) [E] 1 * page 197, lines 10-11 *
by applicantUS13001
 WO2005047899
 WO2009077990
 WO2009077954
 WO2010143158
 WO2011163502
 WO2012066488
 WO2012074785
 WO2012077049
 WO2012077051
 WO2012109544
 WO2012125305
 WO2013062947
 WO2013070600
 WO2013071203
 WO2013171687
 WO2013171694
 WO2014206966
 WO2015005305
 WO2015007830
 WO2015009545
 WO2015019325
    - MURPHY P. M. ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, (1992), vol. 267, pages 7637 - 7643
    - GAVINS F. N. E ET AL., TRENDS IN PHARMACOLOGICAL SCIENCES, (2010), vol. 31, pages 266 - 276
    - CATTANEO F. ET AL., INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, (2013), vol. 14, no. 4, pages 7193 - 7230
    - DUFTON N ET AL., THE JOURNAL OF IMMUNOLOGY, (2010), vol. 184, pages 2611 - 2619
    - LE Y ET AL., TRENDS IN IMMUNOLOGY, (2002), vol. 23, no. 11, pages 541 - 548
    - KRISHNAMOORTHY S, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (2010), vol. 107, no. 4, pages 1660 - 1665
    - LI B. Q ET AL., BLOOD, (2001), vol. 97, pages 2941 - 2947
    - SOGAWA Y ET AL., IMMUNOLOGY, (2011), vol. 132, pages 441 - 450
    - SUMMERS C ET AL., TRENDS IN IMMUNOLOGY, (2010), vol. 31, pages 318 - 324
    - KIM S. D ET AL., EXPERIMENTAL & MOLECULAR MEDICINE, (2013), vol. 13, no. 45, page E40
    - TAE Y. M ET AL., THE JOURNAL OF IMMUNOLOGY, (2012), vol. 188, pages 1799 - 1808
    - KIM S. D ET AL., THE JOURNAL OF IMMUNOLOGY, (2010), vol. 185, pages 4302 - 4310
    - KIM S. D ET AL., PLOS ONE, vol. 7, no. 1, page E30522
    - MIN H. E ET AL., ACTA PHARMACOLOGIC A SINICA, (2011), vol. 32, pages 601 - 610
    - NANAMORI M ET AL., MOLECULAR PHARMACOLOGY, (2004), vol. 66, pages 1213 - 1222
    - BURLI R. W ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2006), vol. 16, pages 3713 - 3718
    - FROHN M ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2007), vol. 17, pages 6633 - 6637
    - CILIBRIZZI A ET AL., JOURNAL OF MEDICINAL CHEMISTRY, (2009), vol. 52, pages 5044 - 5057
    - KIRPOTINA L. N ET AL., MOLECULAR PHARMACOLOGY, (2010), vol. 77, pages 159 - 170
    - SCHEPETKIN I. A ET AL., MOLECULAR PHARMACOLOGY, (2011), vol. 79, pages 77 - 90
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.